{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-07-23-016",
    "source_story_id": "tmp-sidebar-cevostamab-fcrh5-myeloma",
    "edition_id": "mp-2026-07-23-morning-0014",
    "edition_url": "https://themachinepress.com/edition/2026-07-23",
    "position": 18,
    "story_type": "ticker",
    "section": "research",
    "editorial_classification": "editorial",
    "headline": "A New Myeloma Target Produced Responses in 44%",
    "slug": "a-new-myeloma-target-produced-responses-in-44",
    "dek": "Cevostamab activated T cells against FcRH5 in a heavily pretreated Phase I population.",
    "summary": "Cevostamab activated T cells against FcRH5 in a heavily pretreated Phase I population.",
    "body_text": "Among 167 patients at the recommended monotherapy dose, 44.3% responded for a median 11.2 months. The investigational drug also caused serious adverse events, including three treatment-related deaths.",
    "why_it_matters": "Cevostamab activated T cells against FcRH5 in a heavily pretreated Phase I population.",
    "limitations": [],
    "importance": 7,
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-23-016/a-new-myeloma-target-produced-responses-in-44",
    "json_url": "https://themachinepress.com/story/mp-2026-07-23-016.json",
    "first_published_at": "2026-07-23T09:00:00.000-04:00",
    "modified_at": "2026-07-23T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-07-23-016-001",
        "text": "Cevostamab activated T cells against FcRH5 in a heavily pretreated Phase I population.",
        "source_ids": [
          "source-2026-07-23-018"
        ],
        "qualification": null
      }
    ],
    "source_ids": [
      "source-2026-07-23-018"
    ],
    "tags": [
      "multiple myeloma",
      "cevostamab",
      "clinical trial"
    ],
    "image_url": null,
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-07-23-018",
      "title": "Penn Medicine via Newswise: Cevostamab Phase I myeloma results",
      "publisher": "Penn Medicine via Newswise",
      "url": "https://www.newswise.com/articles/new-therapeutic-target-expands-options-for-multiple-myeloma",
      "canonical_url": "https://www.newswise.com/articles/new-therapeutic-target-expands-options-for-multiple-myeloma",
      "source_type": "secondary_reporting",
      "is_primary_source": false,
      "published_at": null,
      "accessed_at": "2026-07-23T08:34:00.000-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-07-23-016-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "A New Myeloma Target Produced Responses in 44%",
    "publisher": "The Machine Press",
    "published_at": "2026-07-23T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-23-016/a-new-myeloma-target-produced-responses-in-44"
  }
}